NEUROCRINE BIOSCIENCES INC (NBIX) 101.22 +2.01 (+2.03%)
101.22 +2.01 (+2.03%)
US64125C1099 - Common Stock - After market: 101.22 0 (0%)
Buy % Consensus
Analysts have set a mean price target of 128.74. This target is 27.19% above the current price.
NBIX was analyzed by 34 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about NBIX.
In the previous month the buy percentage consensus was at a similar level.
NBIX was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-03-30 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2023-03-03 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2023-02-07 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-02-07 | Mizuho | Maintains | Neutral |
| 2023-02-07 | RBC Capital | Maintains | Sector Perform |
| 2023-02-07 | Barclays | Maintains | Overweight |
| 2023-02-07 | Wedbush | Maintains | Outperform |
| 2023-02-07 | Wells Fargo | Maintains | Equal-Weight |
| 2023-02-07 | Piper Sandler | Maintains | Neutral |
| 2023-02-07 | Citigroup | Maintains | Buy |
| 2023-02-07 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-03 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2022-11-14 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2022-11-03 | Raymond James | Maintains | Outperform |
| 2022-11-03 | JP Morgan | Maintains | Overweight |
| 2022-11-02 | Cantor Fitzgerald | Maintains | Overweight |
| 2022-11-02 | Mizuho | Maintains | Neutral |
| 2022-11-02 | RBC Capital | Maintains | Sector Perform |
| 2022-11-02 | SVB Leerink | Maintains | Market Perform |
| 2022-11-02 | Wells Fargo | Maintains | Equal-Weight |
| 2022-11-02 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-02 | Piper Sandler | Maintains | Neutral |
| 2022-10-24 | Citigroup | Maintains | Buy |
| 2022-10-20 | Mizuho | Maintains | Neutral |
| 2022-10-11 | UBS | Initiate | Buy |
| 2022-09-26 | Wells Fargo | Initiate | Equal-Weight |
| 2022-08-08 | Mizuho | Maintains | Neutral |
| 2022-08-05 | Barclays | Maintains | Overweight |
| 2022-07-15 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-04-12 | Barclays | Maintains | Overweight |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA